Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Ligand Pharmaceuticals, Inc.
- Market Cap
- Unavailable
- Volume
- 152.5K
About
Ligand Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise, primarily engaged in sourcing and advancing innovative technologies. These technologies are instrumental in assisting other pharmaceutical businesses with the identification and progression of new therapeutic solutions. The company's portfolio includes medications such as evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. Ronald M. Evans founded the organization in 1987, and its principal corporate offices are located in San Diego, California.
Quick stats
Shares outstanding19.9M
Computed float18.9M
Float / shares94.7%
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000886163
Websitehttp://www.ligand.com
AI Summary
AI-generated1/38
majorbullishearnings
Ligand Reports Second Quarter 2026 Financial Results
Ligand reported Q2 revenue of $63.7 million, up 34% year-over-year, driven by a 32% increase in royalty revenue to $48.0 million. Adjusted EPS reached $2.37, reflecting strong year-over-year growth supported by gains from its royalty portfolio and strategic investments.
The company closed the XOMA Royalty acquisition, adding over 120 assets, and completed a $700 million 0% convertible debt financing. These moves significantly expand Ligand's portfolio and strengthen its capital position with $1.36 billion in cash and equivalents.
Management reaffirmed full-year revenue guidance of $270 million to $310 million and raised the low end of its Adjusted EPS guidance range to $9.00 to $9.50. The increase is attributed to cost synergies from the XOMA deal and incremental interest income from the new notes.